![Heather Huet](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Heather Huet
Technik-/Wissenschafts-/F&E-Leiter bei
DAY ONE BIOPHARMACEUTICALS, INC.
Profil
Heather Adkins Huet is currently the Director at Gammadelta Therapeutics Ltd. and the Chief Scientific Officer at Day One Biopharmaceuticals, Inc. Dr. Huet holds a doctorate from Harvard University and completed undergraduate studies at The University of Texas at Austin.
Aktive Positionen von Heather Huet
| Unternehmen | Position | Beginn |
|---|---|---|
| DAY ONE BIOPHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Gammadelta Therapeutics Ltd.
 Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Operates biotechnology company that engages in discovery and development of allogeneic gamma delta T cell therapies for cancer | Direktor/Vorstandsmitglied | - |
Ausbildung von Heather Huet
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
12
Beziehungen ersten Grades
4
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Texas at Austin
 The University of Texas at Austin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gammadelta Therapeutics Ltd.
Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Operates biotechnology company that engages in discovery and development of allogeneic gamma delta T cell therapies for cancer | Health Technology |
Day One Biopharmaceuticals, Inc.
 Day One Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biopharmaceutical company which develops and commercializes targeted therapies for cancers | Health Technology |
